These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 6908995)

  • 1. [Mechanisms of action and clinical importance of C3-nephritic-factor (author's transl)].
    Lanzer G; Pogglitsch H; Tilz GP
    Acta Med Austriaca; 1981; 8(1):7-13. PubMed ID: 6908995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress in the knowledge of complement. II. Nephritic factors].
    Leibowitch J; Lesavre P
    Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effects of C3 nephritic factor on the complement system--with special reference to stabilizing effect on C3 convertase (C3bBb) activity (author's transl)].
    Nakanishi I
    Nihon Jinzo Gakkai Shi; 1981 Jun; 23(6):719-32. PubMed ID: 6914399
    [No Abstract]   [Full Text] [Related]  

  • 4. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of complement by autoimmune antibodies isolated from sera of patients with membranoproliferative glomerulonephritis and systemic lupus erythematosus.
    Daha MR; Van Es LA
    Neth J Med; 1982; 25(7):202-7. PubMed ID: 6924073
    [No Abstract]   [Full Text] [Related]  

  • 6. Further evidence for the antibody nature of C3 nephritic factor (C3NeF).
    Daha MR; van Es LA
    J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.
    Daha MR; Van Es LA
    Immunology; 1981 May; 43(1):33-8. PubMed ID: 6166544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis.
    Spitzer RE; Stitzel AE; Tsokos GC
    Clin Immunol Immunopathol; 1990 Oct; 57(1):10-8. PubMed ID: 1697516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
    Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
    Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
    Sobel AT; Cooper NR; Schreiber RD
    J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of nephritic factor as an immunoglobulin.
    Williams DG; Bartlett A; Duffus P
    Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial incidence of C3 nephritic factor, partial lipodystrophy and membranoproliferative glomerulonephritis.
    Power DA; Ng YC; Simpson JG
    Q J Med; 1990 Apr; 75(276):387-98. PubMed ID: 2385743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies of complement, nephritic factor, and circulating immune complexes in chronic mesangiocapillary glomerulonephritis types I and II (author's transl)].
    Mirapeix E; Yagüe J; Vives J; Revert L
    Med Clin (Barc); 1981 Jun; 77(1):21-6. PubMed ID: 7253758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.
    Gewurz AT; Imherr SM; Strauss S; Gewurz H; Mold C
    Clin Exp Immunol; 1983 Oct; 54(1):253-8. PubMed ID: 6616970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of carbohydrate in the structure and function of nephritic factor.
    Scott DM; Amos N; Bartolotti SR
    Clin Exp Immunol; 1981 Oct; 46(1):120-9. PubMed ID: 6802534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.